Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Nektar is a clinical-stage biopharmaceutical company focused on immunotherapy. Its primary asset is rezpegaldesleukin, a first-in-class resolution therapeutic for autoimmune diseases (atopic dermatitis, alopecia areata, and Type 1 diabetes). The company also develops NKTR-255 (oncology) and NKTR-0165/0166 (autoimmune). Following the termination of its collaboration with Eli Lilly in 2023, Nektar regained full rights to rezpegaldesleukin and now bears all development costs.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Total Revenue | $55.2 million | $98.4 million |
| Net Loss | $(164.1) million | $(119.0) million |
| Operating Loss | $(140.1) million | $(105.2) million |
| Research & Development (R&D) Expense | $117.3 million | $120.9 million |
| Cash and Investments | $245.8 million | $269.1 million |
| Net Cash Used in Operating Activities | $(208.5) million | $(175.7) million |
Note: Revenue is primarily non-cash royalty revenue related to the sale of future royalties. Product sales revenue was $0 in 2025 following the sale of the Huntsville manufacturing facility in December 2024.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 44% to $55.2 million, driven by the cessation of product sales ($33.6 million in 2024) following the sale of the manufacturing facility and a 15% decrease in non-cash royalty revenue.
- Increased Net Loss: Net loss widened by 38% to $164.1 million, primarily due to the absence of the $40.4 million gain on the sale of the Huntsville facility recorded in 2024 and increased operating expenses.
- Restructuring Costs: Restructuring and impairment charges decreased 40% to $9.3 million (from $15.7 million), though the company continues to incur costs related to subleasing San Francisco facilities.
- Equity Method Investment Loss: A new loss of $8.7 million was recorded from the equity method investment in Gannet BioChem (the buyer of the manufacturing facility), reflecting the buyer's preferred dividend structure and net losses.
Guidance, Outlook, and Risks
Clinical Progress and Outlook
- Rezpegaldesleukin (Atopic Dermatitis): The Phase 2b REZOLVE-AD trial met its primary endpoint at week 16. Maintenance data (announced Feb 2026) showed sustained disease control at week 52. The company expects to initiate a Phase 3 program in 2026, which will significantly increase R&D costs.
- Rezpegaldesleukin (Alopecia Areata): The Phase 2b REZOLVE-AA trial met its primary endpoint when excluding four patients with eligibility violations. The company is evaluating next steps.
- Rezpegaldesleukin (Type 1 Diabetes): A Phase 2 study with TrialNet is underway.
Liquidity and Capital Resources
- Cash Position: As of Dec 31, 2025, cash and investments totaled $245.8 million. Management believes this is sufficient to fund operations for at least the next 12 months.
- Recent Financing (Subsequent Events): In February 2026, Nektar completed an underwritten public offering raising approximately $432.0 million. Additionally, $44.1 million was raised via an At-The-Market (ATM) offering in early 2026.
Key Risks and Contingencies
- Litigation:
- Eli Lilly: Nektar is suing Lilly for breach of contract regarding the rezpegaldesleukin collaboration. A jury trial is scheduled for September 8, 2026.
- Securities Class Action: A putative class action lawsuit (Schramke v. Nektar) was filed in March 2026 alleging misleading statements regarding the REZOLVE-AA trial. Nektar denies the claims.
- Supply Chain: Nektar is solely dependent on Gannet BioChem for the supply of PEG reagents used in manufacturing rezpegaldesleukin and NKTR-255.
- Regulatory: Rezpegaldesleukin has received Fast Track designation for atopic dermatitis and alopecia areata, but approval is not guaranteed.
Investor Verification Checklist
- Phase 3 Funding: Verify the specific budget and timeline for the upcoming Phase 3 atopic dermatitis trial, as this will be the primary driver of cash burn in 2026.
- REZOLVE-AA Data Integrity: Review the details regarding the four patients with eligibility violations in the alopecia areata trial and the company's plan to address the resulting securities litigation.
- Liquidity Runway: Confirm the updated cash runway post the February 2026 capital raise ($432M + $44M) to assess dilution risk and funding sufficiency for Phase 3.
- Supply Agreement Terms: Review the supply agreement with Gannet BioChem to understand pricing, volume commitments, and termination rights for PEG reagents.
- Non-Cash Revenue: Distinguish between cash and non-cash revenue; note that the majority of 2025 revenue was non-cash royalty accounting entries, not cash inflows.